AI Drug Rentosertib Shows Promise in Slowing Ageing

Rentosertib, an experimental drug developed by Insilico Medicine using artificial intelligence (AI), has shown early signs of reducing biological ageing markers while treating idiopathic pulmonary fibrosis (IPF), a serious lung disease. Findings from a Phase IIa clinical trial, published in Nature Biotechnology, revealed that blood-protein data from 42 patients indicated a reduction in predicted biological age when treated with rentosertib.

The drug targets TNIK, a protein involved in fibrosis and ageing-related processes, identified through AI-driven research. The trial evaluated 43 patients over 12 weeks, reporting dose-related improvements in forced vital capacity, a key lung function measure.

Insilico has advanced rentosertib into Phase III clinical development for IPF, announcing the start of the late-stage trial in July 2026 after positive Phase IIa results. While the findings suggest potential for addressing age-related diseases, further research is needed to determine clinical significance, as the study's small sample size limits broader conclusions about ageing reversal.